ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
30 announcements with these filters
Fredun Pharmaceuticals allotted 3,61,599 equity shares following the conversion of 1,20,533 warrants. This allotment was executed at an issue price of Rs. 1,250 per warrant.
Fredun Pharmaceuticals acquired a 26% stake in ₹300 Crore-valued Goodman Vetcare, a dedicated pet pharmacy chain. Plans target PAN-India expansion with ~₹100 Cr revenue by FY31.
Fredun Pharmaceuticals allotted 2,71,200 equity shares following the conversion of 90,400 warrants. The board approved the issuance, raising Rs 11.3 Crore in total consideration.
Fredun Pharmaceuticals announced expansion of its Furlicks pet wellness range from 6 to 22 SKUs. The press release signals accelerated growth in the pet wellness segment.
Fredun Pharmaceuticals acquires pet-wellness brand Furlicks from USV and Wellbeing Nutrition. The deal marks strategic entry into India's pet-wellness market with plans to launch 44 new SKUs.
Fredun Pharmaceuticals launched PAWTALKS, a digital knowledge platform for pet and animal healthcare. Initially debuting on YouTube and Instagram, it connects veterinary experts with pet owners.
Fredun Pharmaceuticals delivered explosive Q1 FY27 growth with standalone income rising 90.44% YoY to INR 228.25 cr and PAT up 94.63% to INR 13.17 cr.
Fredun Pharmaceuticals submitted its Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its prior preferential allotment.
Fredun Pharmaceuticals reported Q1 FY27 total income of ₹228.25 Crore, a 90% YoY increase. Net profit rose 94.6% to ₹13.17 Crore during the same period.
Fredun Pharmaceuticals Ltd reported revenue from operations of ₹227.8 Cr (+90.8% YoY) and net profit of ₹13.1 Cr (+92.6% YoY) for Q1 FY27.
Fredun Pharmaceuticals Ltd has scheduled a board meeting on August 5, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Fredun Pharmaceuticals allotted 1.10 crore bonus shares in a 2:1 ratio. Post-issue paid-up capital increased to Rs 16.54 crore from Rs 5.51 crore.
Fredun Pharmaceuticals set July 16, 2026, as the record date for its 2:1 bonus issue. Shareholders will receive two new shares for every one held.
Fredun Pharmaceuticals held its 39th Annual General Meeting on June 30, 2026. The meeting covered ordinary and special resolutions, including dividend declarations.
Fredun delivered strong Q4 FY26 performance with 27% revenue growth and 56% PAT growth. Transitioning from contract manufacturing to high-margin consumer brands in pet care, mobility, and anti-aging segments.
Fredun Pharmaceuticals reported strong Q3 FY'26 results with 57% revenue growth and 96% PAT growth, driven by its 'new-age' brands in pet care, nutrition, and dermaceutics.
Fredun Pharmaceuticals set June 23, 2026, as the record date for a 7% final dividend. The payment remains subject to shareholder approval at the upcoming AGM.
Fredun Pharmaceuticals scheduled its 39th AGM for June 30, 2026. The share transfer books will remain closed from June 24 to June 30 for meeting purposes.
Fredun Pharmaceuticals released its FY2025-26 Annual Report and 39th AGM notice. Shareholders will vote on a 2:1 bonus issue and a 7% final dividend.
Fredun Pharmaceuticals filed its FY26 Annual Secretarial Compliance Report. The auditor noted temporary board composition non-compliance due to an executive director's sudden demise.
Fredun Pharmaceuticals reported audited FY26 financial results and recommended a 7% final dividend. The board also approved a 2:1 bonus share issue and increased authorized capital.
Fredun Pharmaceuticals announced a 2:1 bonus issue following strong FY26 performance. The move reflects management's confidence in long-term growth and commitment to shareholder wealth.
Fredun Pharmaceuticals reported FY26 revenue of ₹639.12 Crore, marking a 40% YoY jump. EBITDA surged 72% while PAT rose ~60% to ₹33.21 Crore.
Fredun Pharmaceuticals Ltd reported revenue from operations of ₹210.4 Cr (+27.2% YoY) and net profit of ₹10.8 Cr (+80.0% YoY) for Q4 FY26.
Fredun Pharmaceuticals approved FY2026 audited financial results and recommended a 7% final dividend. The board also proposed a 2:1 bonus share issue and increased authorized capital.
Fredun Pharmaceuticals announced a new 40,000 sq. ft. manufacturing facility in Palghar, Maharashtra, its fifth unit. The plant, expected to be operational by October 2026, will support veterinary and nutraceutical production. A further 50,000 sq. ft. expansion is also planned, strengthening the company's manufacturing footprint and scalability to meet domestic and international demand.
Fredun Pharmaceuticals Ltd (BSE: 539730) confirmed it does not qualify as a 'Large Corporate' under SEBI debt-raising norms for the 2026 financial year. The company reported outstanding borrowings of ₹216.43 Crore as of March 31. This routine regulatory disclosure provides transparency regarding the company's borrowing framework and debt market compliance status.
Fredun Pharmaceuticals Ltd promoters Fredun Nariman Medhora and others acquired 40,000 equity shares through the conversion of warrants on April 09, 2026. This conversion increases the total paid-up capital to 5,51,26,900 shares. The promoter group's voting rights increased from 44.17% to 44.57% following the allotment.
Fredun Pharmaceuticals Ltd allotted 40,000 equity shares to Director Daulat Nariman Medhora following the conversion of warrants. The transaction is valued at ₹5.0 Crore. This allotment increases the director's shareholding from 25.78% to 26.32%.
Fredun Pharmaceuticals Ltd allotted 40,000 equity shares to promoter Mrs. Daulat Nariman Medhora following the conversion of warrants. The transaction involved a balance payment of ₹3.75 Crore at an issue price of ₹1250 per share. This conversion completes the warrant exercise, resulting in nil warrants outstanding for this allottee.